In contrast, higher baseline IGF-1 levels were linked to better performance on executive function tasks, such as the Trail Making Test B (TMT-B), in AD patients, indicating a potential protective effect of IGF-1 against cognitive decline [137]. Here, IGF1 is linked to Alzheimer disease.